Abuse potential of Soma®: The GABAA receptor as a target

Molecular and Cellular Pharmacology

Volumn 1, Issue 4, 2009, Pages 180-186

  Gonzalez, Lorie A ^a   Gatch, Michael B ^a   Forster, Michael J ^a   Dillon, Glenn H ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Carisoprodol; Discrimination; GABAA receptor; Meprobamate; Muscle relaxant; Substance abuse

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BARBITURIC ACID DERIVATIVE; BEMEGRIDE; BENZODIAZEPINE DERIVATIVE; CARISOPRODOL; CYTOCHROME P450 2C19; FELBAMATE; FLUMAZENIL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; MEPROBAMATE; OXYCODONE;

ARTICLE; DRUG ABUSE; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HUMAN; NEUROMODULATION; NONHUMAN; TRANQUILIZING ACTIVITY;

EID: 77951484366     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.09.21     Document Type: Article

References (55)

1. Luo X, Pietrobon R, Curtis LH, et al. Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States. Spine 2004;29:E531-7.
2. United States Department of Justice Drug Enforcement Administration Office of Diversion Control. Drugs and chemicals of concern--carisoprodol [internet]. 2009 June [cited 2009 Aug 12]; Available from: http://www. deadiversion.usdoj.gov/drugs-concern/carisoprodol.htm.
3. Eddy NB, Friebel H, Hahn KJ, et al. Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. Bull World Health Organ 1969;40:1-53.
4. Sikdar S, Basu D, Malhotra AK, et al. Carisoprodol abuse: a report from India. Acta Psychiatr Scand 1993;88:302-3.
5. Rust GS, Hatch R, Gums JG. Carisoprodol as a drug of abuse. Arch Fam Med 1993;2:429-32.
6. Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: a drug of continuing abuse. J Am Osteopath Assoc 1997;97:723-4.
7. Littrell RA, Hayes LR, Stillner V. Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 1993;86:753-6.
8. Cady R. Special report. Skeletal muscle relaxants: A new rationale for choice. Prim Care Spec Ed 2003;7:1-14.
9. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991;44:1223- 6.
10. Heacock C, Bauer MS. Tolerance and dependence risk with the use of carisoprodol. Am Fam Physician 2004;69:1622-3.
11. Reeves RR, Algood TL, Wise PM. Skeletal muscle relaxants and associated medications for nonspecific acute back pain. P&T 2005;30:518-24.
12. Chop WM, Jr. Should carisoprodol be a controlled substance? Arch Fam Med 1993;2:911.
13. Reeves RR, Carter OS, Pinkofsky HB. Use of carisoprodol by substance abusers to modify the effects of illicit drugs. South Med J 1999;92:441.
14. Reeves RR, Liberto V. Abuse of combinations of carisoprodol and tramadol. South Med J 2001;94:512-4.
15. Drug Abuse Warning Network. The DAWN report: narcotic analgesics, 2002 update [internet]. [cited 2009 Aug 12]; Available from: http://dawninfo.samhsa. gov/old-dawn/pubs-94-02/shortreports/files/DAWN-tdr-na2002.pdf.
16. Schwilke EW, Sampaio dos Santos MI, Logan BK. Changing patterns of drug and alcohol use in fatally injured drivers in Washington State. J Forensic Sci 2006;51:1191-8.
17. Reeves RR, Hammer JS, Pendarvis RO. Is the frequency of carisoprodol withdrawal syndrome increasing? Pharmacotherapy 2007;27:1462-6.
18. Maxwell JC. Sustance abuse trends in Texas: June 2008 [internet]. [cited 2009 12 Aug]; Available from: http://www.utexas.edu/research/cswr/gcattc/ documents/June2008.pdf.
19. United States Drug Enforcement Administration. DEA briefs & background, drugs and drug abuse, state factsheets, California [internet]. 2008 March [cited 2009 12 Aug]; Available from: http://www.usdoj.gov/dea/pubs/state- factsheets/california.html.
20. Robertson MD, Marinetti LJ. Carisoprodol - effects on human performance and behavior. Forensic Sci Rev 2003:1-9.
21. Bailey DN, Briggs JR. Carisoprodol: an unrecognized drug of abuse. Am J Clin Pathol 2002;117:396-400.
22. Akins BE, Miranda E, Lacy JM, et al. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009;54:495-6.
23. Reeves RR, Burke RS. Is it time for carisoprodol to become a controlled substance at the federal level? South Med J 2008;101:127-8.
24. Cable News Network. Keeping them honest. In: Anderson Cooper 360.
25. Jonsson A, Holmgren P, Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci Int 2004;143:53-9.
26. Chung H, Park M, Hahn E, et al. Recent trends of drug abuse and drug-associated deaths in Korea. Ann N Y Acad Sci 2004;1025:458-64.
27. Bramness JG, Furu K, Engeland A, et al. Carisoprodol use and abuse in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2007;64:210-8.
28. World Health Organization. WHO pharmaceuticals newsletter, No. 5 [internet]. 2007 [cited 2009 Aug 12]; Available from: http://www.who.int/ medicines/publications/newsletter/PN-No6-2007.pdf.
29. Douglas JF, Ludwig BJ, Schlosser A. The metabolic fate of carisoprodol in the dog. J Pharmacol Exp Ther 1962;138:21-7.
30. Dalen P, Alvan G, Wakelkamp M, et al. Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics 1996;6:387-94.
31. Olsen H, Koppang E, Alvan G, et al. Carisoprodol elimination in humans. Ther Drug Monit 1994;16:337-40.
32. Koe BK, Minor KW, Kondratas E, et al. Enhancement of benzodiazepine binding by methaqualone and related quinazolines. Drug Dev Res 1986;7:255-68.
33. Squires RF, Casida JE, Richardson M, et al. [35S]t- butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to gamma-aminobutyric acid-A and ion recognition sites. Mol Pharmacol 1983;23:326-36.
34. Roache JD, Griffiths RR. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 1987;243:978-88.
35. Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997;280:1383-91.
36. Roth BA, Vinson DR, Kim S. Carisoprodol-induced myoclonic encephalopathy. J Toxicol Clin Toxicol 1998;36:609-12.
37. Ellenhorn MJ, Barceloux D. Medical toxicology: diagnosis and treatment of human poisoning. New York: Elsevier Science Publishing; 1988.
38. Gonzalez LA, Gatch MB, Taylor CM, et al. Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther 2009;329:827-37.
39. Holtzman SG, Locke KW. Neural mechanisms of drug stimuli: experimental approaches. Psychopharmacol Ser 1988;4:138-53.
40. Woods JH, Bertalmio AJ, Young AM, et al. Receptor mechanisms of opioid drug discrimination. In: Colpaert FC, Blaster RL, editors. Transduction Mechanisms of Drug Stimuli. Berlin: Springer; 1988. p. 95-106.
41. Stolerman IP. Drug discrimination. In: Van Haaren F, editor. Methods in Behavioral Pharmacology. Amsterdam: Elsevier; 1993. p. 217-43.
42. Balster RL. Drug abuse potential evaluation in animals. Br J Addict 1991;86:1549-58.
43. van der Kleijn E. Kinetics of distribution and metabolism of ataractics of the meprobamate-group in mice. Arch Int Pharmacodyn Ther 1969;178:457-80.
44. Amin J. A single hydrophobic residue confers barbiturate sensitivity to gamma- aminobutyric acid type C receptor. Mol Pharmacol 1999;55:411-23.
45. Korpi ER, Grunder G, Luddens H. Drug interactions at GABA(A) receptors. Prog Neurobiol 2002;67:113-59.
46. Hosie AM, Wilkins ME, da Silva HM, et al. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 2006;444:486-9.
47. Gonzalez LA, Gatch MB, Forster MJ, et al. Carisoprodol acts at GABAA receptors in a subunit-dependent manner. Soc Neurosci Abst 2008:531.9/D10.
48. Ito T, Suzuki T, Wellman SE, et al. Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Life Sci 1996;59:169-95.
49. Pericic D, Strac DS, Jembrek MJ, et al. Prolonged exposure to gamma-aminobutyric acid up-regulates stably expressed recombinant alpha 1 beta 2 gamma 2s GABAA receptors. Eur J Pharmacol 2003;482:117-25.
50. Kumar S, Kralic JE, O'Buckley TK, et al. Chronic ethanol consumption enhances internalization of alpha1 subunit-containing GABAA receptors in cerebral cortex. J Neurochem 2003;86:700-8.
51. Wafford KA. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 2005;5:47-52.
52. Laviolette SR, Gallegos RA, Henriksen SJ, et al. Opiate state controls bi-directional reward signaling via GABAA receptors in the ventral tegmental area. Nat Neurosci 2004;7:160-9.
53. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003;70:S13-40.
54. Schechter MD. Specific antagonism of the behavioral effects of chlordiazepoxide and pentobarbital in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:359-64.
55. Pugh SL, Boone MS, Emmett-Oglesby MW. Tolerance, cross-tolerance and withdrawal in rats made dependent on diazepam. J Pharmacol Exp Ther 1992;262:751-8.